

NHS Greater Glasgow & Clyde Molecular Diagnostic Pathway Development

Joint Working Executive Summary

Joint Working Partner(s)	<p>NHS Greater Glasgow & Clyde</p> <p>Novartis Pharmaceuticals UK Limited</p> <p>Celgene Limited</p>
Project period	Project extended for a further 12 months. It started in January 2015 and will now end in July 2019.
Joint working project summary:	<p>This Joint Working Project aims to introduce new molecular techniques into routine clinical practice. The project aims at achieving the following objectives:</p> <ol style="list-style-type: none"> 1. Identifying companion or stand-alone diagnostics for introduction in patient pathways across Scotland and to inform on the current Scottish process to approve the mentioned companion or stand-alone diagnostics for the relevant medicines carried out by the Molecular Pathology Evaluation Panel (“MPEP”)/ Molecular Pathology Consortium (“MPC”) (The “Scottish Process”) 2. Developing pathways across Scotland incorporating relevant companion or stand-alone diagnostics and appropriate sequential testing strategies including Next Generation Sequencing (“NGS”) and other novel technologies to routine practice 3. Development and evaluation of bioinformatics pipelines for somatic cancer in collaboration with University of Glasgow colleagues 4. Develop a protocol to evaluate genomic signatures in response to chemotherapy 5. Provide a finalised protocol for genetic testing to support clinical trials 6. Capture and utilize the project service data to demonstrate that the service is financially sustainable for NSD 7. Attend a Scotland wide educational meeting where the NHS, academia and industry are represented to promote the benefits of Joint Working Project between industry and the NHS in Scotland
Expected patient outcomes for this project	The Project extension shall aim at furthering and consolidating the objectives already achieved through the Project in the previous year, and namely improving patient outcomes by incorporating a prognostic and diagnostic tool in the relevant patient pathways across Scotland, for specific drugs to be identified, by optimising the use of medicines in suitable patients.

Start Date & Duration	January 2015 Amendment agreement: June 2018 Project end date: July 2019